Earnings To Watch: Medifast (MED) Reports Q2 Results Tomorrow
Medifast (NYSE: MED) will report Q2 results Monday after market hours. The prior quarter revenue was $76.04 million, down 34.3% year over year, and EPS guidance for next quarter exceeded analysts’ expectations. For the upcoming quarter, analysts expect revenue down 31.1% year over year. MED shares are down 10.9% over the past month; average price target is $12 vs $9.83.
How this was made
The 30-second read
Why it matters
Traders can use the stated consensus revenue decline (31.1% YoY) and the company’s recent revenue-miss pattern to position for earnings volatility, but there is no new fundamental disclosure in the text itself.
Market read
This is a pre-earnings checklist for MED with consensus expectations and peer read-through, useful for timing and scenario planning.
What to watch
The article does not discuss margin, cash flow, or guidance details for the quarter, which are often the true drivers of post-earnings repricing.
Background
The piece frames Medifast’s upcoming Q2 earnings, referencing last quarter’s revenue decline and EPS guidance strength, plus recent history of missing revenue estimates.
Ticker impact
Medifast (MED) is set to report Q2 results Monday after market hours, with consensus expecting a 31.1% YoY revenue decline.
Likely volatility around the after-hours print, with direction dependent on whether revenue decline and EPS guidance beat or miss expectations.
The text is a pre-earnings setup: it cites expected YoY revenue decline, notes recent revenue estimate misses, and provides no fresh guidance or results beyond prior-quarter context.
Market effects
Limited read-through to consumer staples; peers cited (Vita Coco, WD-40) are used only as directional context, not as new sector data.
Primarily US small/mid-cap earnings flow; no explicit cross-region linkage.
Low, as the article is company-specific and does not introduce global macro or supply-chain shocks.
Counterpoint
If MED’s EPS guidance strength persists, the market may tolerate revenue contraction, making the stock’s recent weakness less predictive of the earnings reaction.
Key entities
- companyMedifast
Subject of the article, reporting Q2 results Monday after market hours.
- companyVita Coco
Peer cited for Q2 results as a directional hint; no new MED-specific catalyst.
- companyWD-40
Peer cited for Q2 results as a directional hint; no new MED-specific catalyst.
